Biolevate Raises €30M Series A for Life Sciences AI

Biolevate, a trailblazer in applying artificial intelligence to the life sciences sector, has successfully closed a €30 million Series A funding round. This significant capital infusion is earmarked to accelerate the company's international expansion, enhance its proprietary platform's capabilities, and broaden its deployment across the life sciences industry.

The funding round was notably co-led by RAISE France, the investment arm of French entrepreneur Aymar Hénin, and Orange Ventures. Further bolstering the round were strategic investments from MSD Global Health Innovation Fund (MGHIF), Station F, and a crucial contribution from existing investor EQT Ventures. This diverse investor base underscores strong confidence in Biolevate's vision and market potential.

Founded in Paris by a team with deep expertise from Dataiku and prominent AI research backgrounds, Biolevate is addressing critical operational inefficiencies within the life sciences. As AI increasingly revolutionizes drug discovery and development, the company recognizes the immense pressure on pharmaceutical firms to streamline the complex scientific and regulatory pathways essential for bringing new therapies to market. The global pharmaceutical market, valued at over $1.4 trillion, is ripe for AI-driven optimization.

Biolevate's core innovation is an enterprise-grade, agentic AI platform designed to transform scientific and regulatory knowledge into verifiable, auditable workflows. A key differentiator is its ability to ensure outputs are firmly rooted in source evidence, enabling life sciences organizations to leverage AI within stringent regulatory frameworks while maintaining essential human oversight. This approach is particularly vital in a sector where compliance and data integrity are paramount.

Initially conceived to expedite regulatory approval processes, Biolevate's platform now spans the entire life sciences value chain. Its applications extend from early-stage research and clinical trials to health technology assessments, regulatory dossier preparation, drug discovery, and development. The platform's capacity to manage up to 100,000 agents concurrently highlights its scalability for complex, data-intensive tasks.

Early performance indicators are compelling. Biolevate reports that its platform has achieved a sixteenfold acceleration in systematic literature reviews and research synthesis. Furthermore, it has delivered an impressive 80% efficiency gain in regulatory intelligence and compliance tasks. Since its seed funding in 2024, the company has cultivated a robust customer base, now serving over a dozen enterprise clients and demonstrating substantial growth in its annual recurring revenue.

The Series A financing coincides with Biolevate's strategic expansion into the United States, marked by the establishment of a new office in Boston. The company has doubled its workforce over the past year and anticipates another doubling in the coming year. Demonstrating its commitment to innovation, Biolevate has also filed seven patent applications across various therapeutic areas, with two already submitted in Europe, signaling its intent to build a strong intellectual property portfolio.